Kane Biotech Announces Extension of Private Placement Offering
April 29 2022 - 3:05PM
Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”)
today announced that it has extended the completion of its
previously announced non-brokered private placement offering (the
“Offering”) by 30 days until May 29, 2022.
The terms of the Offering remain unchanged from
those described in the press release dated March 15, 2022 and the
Offering remains subject to receipt of all necessary approvals,
including the approval of the TSX Venture Exchange.
This press release does not constitute
an offer to sell or the solicitation of an offer to buy these
securities, nor shall it constitute an offer, solicitation or sale
in any jurisdiction in which such offer, solicitation or sale is
unlawful. These securities have not been, and will not be,
registered under the United States Securities Act of 1933, as
amended, or any state securities laws, and may not be offered or
sold in the United States or to U.S. persons unless registered or
exempt therefrom.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research,
development and commercialization of technologies and products that
prevent and remove microbial biofilms. The Company has a portfolio
of biotechnologies, intellectual property (81 patents and patents
pending, trade secrets and trademarks) and products developed by
the Company's own biofilm research expertise and acquired from
leading research institutions. StrixNB™, DispersinB®, Aledex™,
bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactiv+®,
DermaKB™ and DermaKB Biofilm™ are trademarks of Kane Biotech. The
Company is listed on the TSX Venture Exchange under the symbol
"KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
For more information: |
|
|
|
|
|
Marc Edwards |
Ray Dupuis |
Nicole Sendey |
Chief Executive Officer |
Chief Financial Officer |
Investor Relations/PR |
Kane Biotech Inc |
Kane Biotech Inc |
Kane Biotech Inc |
medwards@kanebiotech.com |
rdupuis@kanebiotech.com |
nsendey@kanebiotech.com |
+1 (514) 910-6991 |
+1 (204) 298-2200 |
+1 (250) 327-8675 |
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Caution Regarding Forward-Looking
InformationThis press release contains certain statements regarding
Kane Biotech Inc. that constitute forward-looking information under
applicable securities law. These statements reflect
management’s current beliefs and are based on information currently
available to management. Certain material factors or assumptions
are applied in making forward-looking statements, and actual
results may differ materially from those expressed or implied in
such statements. These risks and uncertainties include, but are not
limited to, risks relating to the Company’s: (a) financial
condition, including lack of significant revenues to date and
reliance on equity and other financing; (b) business, including its
early stage of development, government regulation, market
acceptance for its products, rapid technological change and
dependence on key personnel; (c) intellectual property including
the ability of the Company to protect its intellectual property and
dependence on its strategic partners; and (d) capital structure,
including its lack of dividends on its common shares, volatility of
the market price of its common shares and public company costs.
Further information about these and other risks and uncertainties
can be found in the disclosure documents filed by the Company with
applicable securities regulatory authorities, available
at www.sedar.com. The Company cautions that the foregoing list
of factors that may affect future results is
not exhaustive.
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Apr 2023 to Apr 2024